Influenza

  1. This web page provides technical information, resources, and links relevant to microarray patch (also known as MAPs or microneedle patches) development of high priority vaccine and essential medicines. Includes multisectoral information for the community of microarray patch researchers, manufacturers, stakeholders, and technology developers.
    Published: November 2018
    Type: Resource Page
  2. Scientists at PATH are leveraging a new tool to develop more effective vaccines to combat some of the world's toughest diseases.
    Published: October 2018
    Type: Article
  3. International collaboration announces successful clinical trial results with licensure expected in 2019
    Published: September 2018
    Type: Press Release
  4. As a nine-year project to build vaccine development capacity worldwide comes to an end, PATH and partners reflect on how far we’ve come.
    Published: September 2018
    Type: Article
  5. Vietnam has been working for nearly a decade to develop and manufacture influenza vaccines. With PATH support, the Institute of Vaccines and Medical Biologicals has done just that—and it has submitted two candidates for licensure.
    Published: September 2018
    Type: Article
  6. How does Vietnam's work on a seasonal influenza vaccine mitigate deadly pandemics?
    Published: September 2018
    Type: Article
  7. Dr. Le Van Be, director of the Institute of Vaccines and Medical Biologicals, believes in the power of vaccines. And he is committed to seeing locally made influenza vaccine become a reality.
    Published: September 2018
    Type: Article
  8. What's it like to volunteer for for a clinical trial? One participant in Vietnam reflects on the opportunity to contribute to the country's influenza defenses.
    Published: September 2018
    Type: Article
  9. Serbia’s Institute of Virology, Vaccines, and Sera “Torlak” is a trusted, recognized vaccine producer in Serbia. As part of the influenza vaccine development project, it conducted its first complex vaccine clinical trial in humans, which helps position Torlak as an essential vaccine producer for the Balkan region.
    Published: September 2018
    Type: Article
  10. Improving vaccine coverage rates and vaccine acceptability in Serbia are critical issues. Locally made vaccines might be a part of the solution.
    Published: September 2018
    Type: Article
Load more